Long-term Empagliflozin Use in Chronic Syndrome of Inappropriate Antidiuresis Due to Traumatic Subarachnoid Hemorrhage
Abstract
Syndrome of inappropriate antidiuresis (SIAD), the leading cause of hyponatremia, poses treatment challenges. Fluid restriction often proves insufficient. Alternative therapies such as demeclocycline, tolvaptan, and urea are limited to selected cases due to frequent side effects, high cost, and low availability, respectively. This case report explores the potential of empagliflozin as a novel treatment option. A 32-year-old female with SIAD following a traumatic subarachnoid hemorrhage experienced persistent hyponatremia despite fluid restriction and initial treatment with hypertonic saline and tolvaptan. Treatment with severe fluid restriction of 800 milliliters/day (mL/day) for almost a year led to significant impairment in her quality of life. Empagliflozin 25 milligrams/day was then initiated, resulting in sustained normonatremia for 16 months, the longest reported duration to date. This allowed increased fluid intake (1750 mL/day) and improved quality of life. Empagliflozin shows potential for managing chronic SIAD; prospective studies are needed to validate its efficacy and safety.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.